VH4524184 / ViiV Healthcare, GSK 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VH4524184 / ViiV Healthcare, GSK
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Completed
2
22
Europe, Canada, US, RoW
VH4524184, Placebo
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/24
06/24
NCT05631704: A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

Recruiting
1
105
US
VH4524184, Midazolam, Placebo
ViiV Healthcare
HIV Infections
08/23
08/23
NCT06310616: A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Completed
1
26
US
VH4524184, Loestrin
ViiV Healthcare
HIV Infections
08/24
08/24
NCT06310551: First Time in Human Study of Long Acting VH4524184 Formulations

Recruiting
1
72
US
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, PH20, Halozyme ENHANZE, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation C SC, Placebo Formulation C SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
ViiV Healthcare, GlaxoSmithKline
HIV Infections
03/27
01/28

Download Options